Important Information for REGN Investors: Deadline to File a Claim is Approaching
If you have invested in REGN Therapeutics Inc. (REGN) and have suffered losses, you may be entitled to compensation. The securities law firm of Hagens Berman urges REGN investors to contact the firm before the Mar. 10, 2025 deadline to discuss your legal rights. The deadline to file a claim is fast approaching, and missing it may result in a forfeiture of your right to recover damages.
Background
REGN Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing innovative therapeutic antibodies for patients with severe and life-threatening diseases. The company’s lead product candidate, REGN-COV2, is an investigational monoclonal antibody cocktail for the treatment and prevention of COVID-19. REGN-COV2 has been authorized for emergency use in the United States, Europe, and other countries.
Allegations of Misconduct
Despite this promising development, the securities class action lawsuit filed against REGN alleges that the company and certain of its executives made materially false and misleading statements regarding the safety and efficacy of REGN-COV2. The complaint alleges that the defendants failed to disclose that REGN-COV2 may cause serious side effects, including infusion reactions and antibody-dependent enhancement (ADE), which can worsen the disease in some patients.
Deadline to File a Claim
The securities class action lawsuit is seeking to recover damages for investors who purchased or otherwise acquired REGN securities between July 28, 2020, and Nov. 18, 2020. If you are a REGN investor and suffered losses during this time frame, you may be entitled to compensation. The deadline to file a claim is Mar. 10, 2025. It is essential to contact Hagens Berman as soon as possible to discuss your potential claim.
Effect on Individual Investors
If the allegations against REGN are proven true, individual investors who purchased REGN securities during the class period may be able to recover their losses. The damages may include the difference between the purchase price and the current value of the securities, as well as any related losses, such as fees and commissions paid to brokers.
Effect on the World
The outcome of this securities class action lawsuit could have significant implications for the biotechnology industry and the development of new treatments for life-threatening diseases. The allegations of misconduct against REGN highlight the importance of transparency and accurate disclosures in the securities market. If the defendants are found liable, it could deter other companies from engaging in similar conduct and encourage greater investor protection.
Conclusion
The Mar. 10, 2025 deadline to file a claim for losses suffered from investing in REGN Therapeutics Inc. is fast approaching. If you are a REGN investor and believe you may be entitled to compensation, contact Hagens Berman as soon as possible to discuss your potential claim. The outcome of this securities class action lawsuit could have far-reaching implications for the biotechnology industry and investor protection.
- REGN Therapeutics Inc. (REGN)
- Securities class action lawsuit
- Misconduct allegations
- Deadline to file a claim: Mar. 10, 2025
- Individual investors’ potential compensation
- Implications for the biotechnology industry and investor protection
